An investigation for investors in Dynavax Technologies Corporation (NASDAQ:DVAX) shares over potential securities laws violations by Dynavax Technologies was announced and NASDAQ:DVAX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 09/06/2016 --An investigation on behalf of investors of Dynavax Technologies Corporation (NASDAQ:DVAX) shares over potential securities laws violations by Dynavax Technologies in connection certain financial statements was announced.

Investors who purchased shares of Dynavax Technologies Corporation (NASDAQ:DVAX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dynavax Technologies Corporation (NASDAQ:DVAX) concerning whether a series of statements by Dynavax Technologies regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 2, 2016, the U.S. Food and Drug Administration ("FDA") announced that it had cancelled Dynavax Technologies Corporation's November 16, 2016 meeting with the Vaccines and Related Biological Products Advisory Committee "to allow time for the FDA to review and resolve several outstanding issues" with Dynavax's Biologics License Application for HEPLISAV-B™. The FDA further stated that it would schedule an Advisory Committee meeting in the future if necessary.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) declined from $16.19 per share to as low as $10.14 per share on September 2, 2016.

Those who purchased shares of Dynavax Technologies Corporation have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com